Michael S. Abrams - 31 Aug 2023 Form 4 Insider Report for Arch Therapeutics, Inc. (ARTHQ)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: ARTHQ
Reported as of: 31 Aug 2023
Net transaction value: +$2,830
SEC form: 4
Accepted by SEC: 08 Sep 2023, 17:47:59 UTC
Prior SEC filing: 10 Nov 2022
Next SEC filing: 22 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ Michael Abrams

Key filing fact

Michael S. Abrams filed Form 4 for Arch Therapeutics, Inc. (ARTHQ) on 08 Sep 2023.

Key facts

This page summarizes Michael S. Abrams's Form 4 filing for Arch Therapeutics, Inc. (ARTHQ).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Sep 2023, 17:47.

Change

Previous filing in this sequence was filed on 10 Nov 2022.
Current net transaction value: +$2,830.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARTH transaction

Common Stock

Purchase

Transaction value: $2,830
Shares: +10,292
Change %
Price: $0.2750^*
Shares after: 10,292
Date: 31 Aug 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARTH transaction Derivative

Warrants (right to buy)

Award

Transaction value
Shares: +20,584
Change %
Price
Shares after: 20,584
Date: 31 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,584
Exercise price: $1.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The warrants are exercisable after the earlier of (A) the six-month anniversary after the date of issuance and (B) the date that a registration statement registering the shares underlying the warrants is declared effective.

Footnote F2

The warrants were sold as part of a unit with the shares of common stock reported in Table I, at a price of $0.275 per share of common stock and accompanying warrant to purchase two shares of common stock.